Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Bio-Reference Laboratories Inc. (NASDAQ: BRLI) shares declined 9.31 percent to close at $26.00 a share Wednesday. The stock traded between $25.86 and $28.24 on volume of 1.42 million shares traded. William Blair has recently downgraded the company’s rating to “market perform” from “outperform” due to proposed Medicare reimbursements cuts. Shares of Bio-Reference Laboratories have gained approximately 9.2 percent year-to-date.
Get more information on Bio-Reference Laboratories and free access to the in-depth equity report at:
www.FiveStarEquities.com/BRLI
Fastenal Company (NASDAQ: FAST) shares declined 2.82 percent to close at $45.77 a share Wednesday. The stock traded between $44.90 and $46.83 on volume of 5.17 million shares traded. The company’s revenues of $847.6 million for the second quarter of 2013 fell short of analysts’ expectations of $857.1 million, according to FactSet. Shares of Fastenal have fallen approximately 2.0 percent year-to-date.
Get more information on Fastenal and free access to the in-depth equity report at:
www.FiveStarEquities.com/FAST
Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) shares spiked 10.10 percent to close at $14.73 a share Wednesday. The stock traded between $13.98 and $14.76 on volume of 8.98 million shares traded. The company expects bookings to exceed $200 million for the second quarter of 2013, bookings for the first quarter totaled roughly $178 million. Shares of Allscripts Healthcare Solutions have gained approximately 56.4 percent year-to-date.
Get more information on Allscripts and free access to the in-depth equity report at:
www.FiveStarEquities.com/MDRX
Nu Skin Enterprises, Inc. (NYSE: NUS) shares soared 19.21 percent to close at $79.36 a share Wednesday. The stock traded between $70.83 and $79.70 on volume of 7.57 million shares traded. The company now expects revenues for the second quarter of 2013 to be approximately $680 million, compared to their previous guidance of $570 to $580 million. Shares of Nu Skin Enterprises have gained approximately 114.0 percent year-to-date.
Get more information on Nu Skin Enterprises and free access to the in-depth equity report at:
www.FiveStarEquities.com/NUS
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com